A cardiac rehabilitation exercise program potentially inhibits progressive inflammation in patients with severe chagas cardiomyopathy: a pilot single-arm clinical trial

thumbnail.default.alt
Data
2020
Autores
Rodrigues Junior, Luiz Fernando
Mendes, Fernanda de Souza Nogueira Sardinha
Pinto, Vivian Liane Mattos
Silva, Paula Simplicio da
Silva, Gilberto Marcelo Sperandio da
Pinheiro, Roberta Olmo
Sousa, Andréa Silvestre de
Mediano, Mauro Felippe Felix
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of Research in Medical Sciences
Resumo
Background: Cardiac rehabilitation exerts anti‑ inflammatory effect on several cardiovascular diseases; however, these effects were not described for Chagas cardiomyopathy, which is associated with pro‑ inflammatory imbalance. Materials and Methods: Ten patients with severe Chagas cardiomyopathy performed 8 months of exercise training in a cardiac rehabilitation program. Interleukin‑ 1 beta (IL‑ 1β ), IL‑ 8, IL‑ 10, interferon gamma (IF‑ γ ), tumor necrosis factor alpha (TNF‑ α ), and monocyte chemoattractant protein‑ 1 (MCP‑ 1) serum levels were measured using enzyme‑ linked immunosorbent assay at baseline, 4, and 8 months. The influence of exercise on cytokine levels was evaluated using the one‑ way analysis of variance for repeated measurements, with Bonferroni posttest for multiple comparisons. Results: Levels of pro‑ inflammatory (TNF‑ α , IL‑ 1β , IL‑ 8, IF‑ γ , and (MCP‑ 1) and anti‑ inflammatory (IL‑ 10) cytokines did not vary significantly during the observation period. Conclusion: Exercise may benefit patients with severe Chagas cardiomyopathy by curbing the production of pro‑ inflammatory cytokines in this disease characterized by a continuous state of inflammation.
Description
Palavras-chave
Cardiac rehabilitation, Chagas cardiomyopathy, Cytokines, Heart failure
Citação
Rodrigues Junior LF, Mendes FSNS, Pinto VLM, Silva PS, Silva GMS, Pinheiro RO, Sousa AS, Mediano MFF. A cardiac rehabilitation exercise program potentially inhibits progressive inflammation in patients with severe Chagas cardiomyopathy: A pilot single-arm clinical trial (Short Communication). J Res Med Sci. 2020; 25(2):18.